Post-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey

Basit Öğe Kaydı
dc.contributor.authorTuglular, Ayse Tulin Firatli
dc.contributor.authorPehlivan, Mustafa
dc.contributor.authorSonmez, Mehmet
dc.contributor.authorHacioglu, Sibel Kabukcu
dc.contributor.authorSaydam, Guray
dc.contributor.authorAyyildiz, Orhan
dc.contributor.authorKaynar, Leylagul
dc.date.accessioned2024-04-24T17:49:57Z
dc.date.available2024-04-24T17:49:57Z
dc.date.issued2022
dc.departmentDicle Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS191en_US
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.startpageS190en_US
dc.identifier.urihttps://hdl.handle.net/11468/23113
dc.identifier.volume22en_US
dc.identifier.wosWOS:000895909200334
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemia
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titlePost-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkeyen_US
dc.titlePost-authorization safety of lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma in Turkey
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu